4Q14 Stock Wrap-up: Grow early, grow often

Biotech stocks rose in 4Q14, with only the microcaps segment, with valuations under $200 million, finishing down. The rally followed two quarters in which only the large cap segment, with valuations over $5 billion, were up.

The fourth quarter saw strong performances by companies new to public markets. In the $500-$999 million tier, eight of the top 10 gainers completed their IPOs in 2013 or 2014, and in the $1-$4.9 billion and $200-$499 million tiers, six and five of the top 10, respectively, closed IPOs in the past two years...